Reuters logo
BRIEF-Oncosec presents positive Phase 2 data for immunopulse® IL-12 in combination with Pembrolizumab
2017年10月19日 / 上午10点16分 / 1 个月前

BRIEF-Oncosec presents positive Phase 2 data for immunopulse® IL-12 in combination with Pembrolizumab

Oct 19 (Reuters) - Oncosec Medical Inc

* Oncosec presents positive Phase 2 data for Immunopulse® IL-12 in combination with Pembrolizumab demonstrating a best overall response rate (BORR) of 50 pct in predicted anti-PD-1 non-responder melanoma patients

* Oncosec - anticipate reporting initial data from PISCES/KEYNOTE-695 in mid-2018​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below